Search research articles
Contact Us
Filters
Showing results (251-260 of 328) with videos related to
Page
of 33
Sort By:
JCI Insight
|
February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Cancer Discovery
|
November 18, 2020
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
Xin Hong, Whijae Roh, Ryan J Sullivan, et al.
EMBO Molecular Medicine
|
April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
JAMA Network Open
|
August 9, 2021
Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
Michael D White, Robert H Klein, Brian Shaw, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Nature Medicine
|
May 9, 2024
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Molly Fisher Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 33
Search research articles
Search
Showing results (251-260 of 328) with videos related to
Sort By:
Page
of 33
JCI Insight
|
February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Cancer Discovery
|
November 18, 2020
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
Xin Hong, Whijae Roh, Ryan J Sullivan, et al.
EMBO Molecular Medicine
|
April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
JAMA Network Open
|
August 9, 2021
Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
Michael D White, Robert H Klein, Brian Shaw, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Nature Medicine
|
May 9, 2024
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Molly Fisher Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 33